Clinical Strategies in the Medical Care of Jehovah's Witnesses

American Journal of Medicine

Volumn 119, Issue 12, 2006, Pages 1013-1018

  Remmers, Paul A ^a   Speer, Alice J ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Blood substitutes; Bloodless medicine; Erythropoietin; Factor VII; Iron detran; Jehovah's Witnesses

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; BLOOD SUBSTITUTE; CYANOCOBALAMIN; DESMOPRESSIN; ERYTHROPOIETIN; FIBRIN GLUE; FOLIC ACID; HEMOGLOBIN; HEMOSPAN; IRON; IRON DEXTRAN; POLYMERIZED HEMOGLOBIN; PYRIDOXYLPOLYHEMOGLOBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HEMOGLOBIN; THROMBIN; TISSUE ADHESIVE; TRANEXAMIC ACID;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ANEMIA; ATTITUDE TO HEALTH; BLEEDING; BLOOD AUTOTRANSFUSION; BLOOD TRANSFUSION; CAUTERIZATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL HEMORRHAGE; HEART LUNG MACHINE; HEMODIALYSIS; HEMODILUTION; HEMOSTASIS; HUMAN; INTENSIVE CARE UNIT; IRON DEFICIENCY ANEMIA; IRON METABOLISM DISORDER; JEHOVAH'S WITNESS; MEDICAL CARE; MEDICAL PRACTICE; OPTIMAL DRUG DOSE; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; POPULATION RISK; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RELIGION; RESUSCITATION; REVIEW; SINGLE DRUG DOSE; SURGICAL EQUIPMENT; TISSUE OXYGENATION; TREATMENT INDICATION; TREATMENT REFUSAL;

ALGORITHMS; ANEMIA; BLOOD SUBSTITUTES; HEMORRHAGE; HUMANS; JEHOVAH'S WITNESSES;

EID: 37849187308     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.04.016     Document Type: Review

References (52)

1. Dixon J.L., and Smalley M.G. Jehovah's Witnesses: the surgical/ethical challenge. JAMA 246 (1981) 471-472
2. Ridley D.T. Jehovah's Witness' refusal of blood: obedience to scripture and religious conscience. J Med Ethics 25 (1992) 469-472
3. Dixon J.L. Blood: whose choice and whose conscience?. N Y State J Med 88 (1988) 463-464
4. Malyon D. Transfusion-free treatment of Jehovah's Witnesses: respecting the autonomous patient's motives. J Med Ethics 24 (1998) 376-381
5. Bodnaruk Z.M., Wong C.J., and Thomas M.J. Meeting the clinical challenge of care for Jehovah's Witnesses. Transfus Med Rev 18 (2004) 105-116
6. Goodnough L.T., Shander A., and Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion 43 (2003) 668-678
7. Goodnough L.T., Brecher M.E., Kanter M.H., and AuBuchon J.P. Medical progress: transfusion medicine (first of two parts)-blood transfusion. N Engl J Med 340 (1999) 438-447
8. Goodnough L.T., Brecher M.E., Kanter M.H., and AuBuchon J.P. Medical progress: transfusion medicine (second of two parts)-blood conservation. N Engl J Med 340 (1999) 525-553
9. Carson J.L., Hill S., Carless P., et al. Transfusion triggers: a systematic review of the literature. Transfus Med Rev 16 (2002) 187-199
10. Hebert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 340 (1999) 409-417
11. Moore E. Staged physiologic restoration and damage control surgery. World J Surg 22 (1998) 1184-1191
12. Bose D. Evolving trends in the care of polytrauma patients. Injury 37 (2006) 20-28
13. Colombo F. Liver trauma: experience in the management of 252 cases. Chir Ital 6 (2005) 695-702
14. Miller R. Complications after 344 damage-control open celiotomies. J Trauma 59 (2005) 1365-1371
15. Grotz M., Gummerson N.W., Gansslen A., et al. Staged management and outcome of combined pelvic and liver trauma. An international experience of the deadly duo. Injury 37 (2006) 642-651
16. Taeger G. Damage control orthopedics in patients with multiple injuries is effective, time saving and safe. J Trauma 59 (2005) 409-416
17. Boffard K.D., Riou B., Warren B., et al. Recombinant factor VIIa as adjunctive therapy for bleeding contron in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 59 (2005) 8-18
18. Martinowitz U., Michaelson M., and The Isreali Multidisplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 3 (2005) 638-639
19. Fridberg M.J., Hedner U., Roberts H.R., and Erhardtsen E. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis 16 (2005) 259-266
20. Hedner U. Mechanism of action of recombinant activated factor VII: an update. Semin Hematol 43 (2006) S105-S107
21. Veneri D., and Franchini M. Successful treatment of intestinal hemorrhage in a Jehovah's Witness patient. Am J Hematol 79 (2005) 344-345
22. Tanaka K.A., Waly A.A., Cooper W.A., and Levy J.H. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa. Anesthesiology 98 (2003) 1513-1515
23. Carson J.L., Noveck H., Berlin J.A., and Gould S.A. Mortality and morbidity in patients with low postoperative Hb levels who decline blood transfusion. Transfusion 42 (2002) 812-818
24. Schalte G., Janz H., Busse J., et al. Life-threatening postoperative blood loss in a Jehovah's Witness, treated with high-dose erythropoietin. Br J Anaesth 94 (2005) 442-444
25. Kulvatunyou N., and Heard S.O. Care of the injured Jehovah's Witness patient: case report and review of the literature. J Clin Anesth 16 (2004) 548-553
26. Nash M.J., and Cohen H. Management of Jehovah's Witness patients with haematological problems. Blood Rev 18 (2004) 211-217
27. Corwin H.L. The role of erythropoietin therapy in the critically ill. Transfus Med Rev 20 (2006) 27-33
28. Garbiel A., Kozek S., Chiari A., et al. High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma 44 (1998) 361-367
29. Corwin H.L., Gettinger A., Pearl R.G., et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 288 (2002) 2827-2835
30. Carson J.L. Should patients in intensive care units receive erythropoietin?. JAMA 288 (2006) 2884-2886
31. Walton T. Erthropoietin use in a Jehovah's Witness patient. Ann Pharmacother 36 (2002) 729-730
32. Price S., Pepper J.R., and Jaggar S.I. Recombinant human erythropoietin use in a critically ill Jehovah's Witness after cardiac surgery. Anesth Analg 101 (2005) 325-327
33. Goodnough L.T., Skikne B., and Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 96 (2000) 823-833
34. Auerbach M., Ballard H., Trout J.R., et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22 (2004) 1301-1307
35. Klein H.G. The prospects for red-cell substitutes. N Engl J Med 342 (2000) 1666-1668
36. Inayat M.S., Bernard A.C., Gallicchio V.S., Garvy B.A., Elford H.L., and Oakley O.R. Oxygen carriers: a selected review. Transfus Apher Sci 34 (2006) 25-32
37. Agrawal Y.P., Freedman M., and Szczepiorkowski Z.M. Long-term transfusion of polymerized bovine hemoglobin in a Jehovah's Witness following chemotherapy for myeloid leukemia: a case report. Transfusion 45 (2005) 1735-1738
38. Cothren C. Blood substitute and erythropoietin therapy in a severely injured Jehovah's Witness. N Engl J Med 346 (2002) 1097-1098
39. Gould S.A., Moore E.E., Hoyt D.B., et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg 187 (1998) 113-122
40. Gould S.A., Moore E.E., Hoyt D.B., et al. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. J Am Coll Surg 195 (2002) 445-452
41. Goodnough L.T., and Despotis G.J. Transfusion medicine: support of patients undergoing cardiac surgery. Am J Cardiovasc Drugs 1 (2001) 337-351
42. Mangano D. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
43. Helm R.E., Rosengart T.K., Gomez M., et al. Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. Ann Thorac Surg 65 (1998) 125-136
44. Sarteschi L.M. Jehovah's Witnesses, blood transfusions and transplantations. Transplant Proc 36 (2004) 499-501
45. Boggi U. Kidney and pancreas transplants in Jehovah's Witnesses: ethical and practical implications. Transplant Proc 36 (2004) 601-602
46. Rubenstein M. Bone marrow transplantation in Jehovah's Witnesses. Leuk Lymphoma 45 (2004) 635-636
47. Wandt H. Two allogenic hematopoietic stem cell transplantations without the use of blood-product support. Haematologica 90 (2005) 1292-1294
48. Jabbour N., Gagandeep S., Mateo R., et al. Transfusion free surgery: single institution experience of 27 consecutive liver transplants in Jehovah's Witnesses. J Am Coll Surg 201 (2005) 412-417
49. Goodnough L.T. Blood and blood conservation: a national perspective. J Cardiothorac Vasc Anesth 18 4 Suppl (2004) 6S-11S
50. Kickler T.S. Why "bloodless medicine" and how should we do it?. Transfusion 43 (2003) 550-551
51. Proposito D., Gramolini R., Corrazza V., et al. Objectives of a bloodless surgery program. A comparative study (major surgery vs. minor-medium surgery) in 51 Jehovah's Witnesses patients. Ann Ital Chir 73 (2002) 197-209
52. Mann M.C., Votto J., Kambe J., et al. Management of the severely anemic patient who refuses transfusion: lessons learned during the care of a Jehovah's Witness. Ann Intern Med 117 (1992) 1042-1048